Analyse et modélisation de l'effet de l'Interleukine 7 chez les patients infectés par le VIH |
|
Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model |
|
Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques. |
|
Apport de la modélisation semi-mécanistique dans l'étude pharmacocinétique/pharmacodynamique des antibiotiques seuls et en combinaison dans la lutte contre les bactéries résistantes |
|
Association Between Tumor Size Kinetics and Survival in Patients With Urothelial Carcinoma Treated With Atezolizumab: Implication for Patient Follow-Up |
|
Can we use viral kinetic models to individualize treatment? |
|
Comprendre et contrôler la transmission des bactéries multirésistantes par l'analyse et la modélisation des réseaux d'interactions interindividuelles en milieu hospitalier |
|
Consideration of multiple events for the analysis and prediction of a cancer evolution |
|
Contribution of semi-mechanistic modelling to pharmacokinetic/pharmacodynamic studies of antibiotics alone and in combination in the fight against resistant bacteria. |
|
COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models |
|
Design evaluation and optimization for models of hepatitis C viral dynamics. |
|
Designing a Pediatric Study for an Antimalarial Drug by Using Information from Adults |
|
Determining Ribavirin's mechanism of action against Lassa virus infection |
|
Dominance of the CD4(+) T helper cell response during acute resolving hepatitis A virus infection. |
|
Early control of viral load by favipiravir promotes survival to Ebola virus challenge and prevents cytokine storm in non-human primates |
|
Early HIV RNA decay during raltegravir-containing regimens exhibits two distinct subphases (1a and 1b). |
|
Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies |
|
Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials |
|
Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C. |
|
Estimating biologically relevant parameters under uncertainty for experimental within-host murine West Nile virus infection. |
|
Estimation in HIV and HCV dynamics models. |
|
Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea |
|
Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted |
|
Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses |
|
Handling data below the quantification limit in viral kinetic modeling for model evaluation and prediction of treatment outcome |
|
Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128) |
|
Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates |
|
Immediate loading and implant-supported prostheses in the completely edentulous maxilla. |
|
Impact of treatment against hepatitis C virus on overall survival of naive patients with advanced liver disease |
|
Inférence dans les modèles dynamiques de population : applications au VIH et au VHC |
|
Inference for random changepoint models : application to pre-dementia cognitive decline. |
|
Innate immune tolerance and the role of kupffer cells in differential responses to interferon therapy among patients with HCV genotype 1 infection |
|
Joint models for a longitudinal semicontinuous biomarker and a terminal event with application to cancer clinical trials. |
|
Lassa viral dynamics in non-human primates treated with favipiravir or ribavirin |
|
Mathematical modeling of bacterial kinetics to predict the impact of antibiotic colonic exposure and treatment duration on the amount of resistant enterobacteria excreted |
|
Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents? |
|
Mise en charge immédiate et bridges implanto-portés chez l’édenté complet maxillaire |
|
Modèles conjoints pour un biomarqueur semi-continu et un événement terminal avec application aux essais cliniques en cancérologie |
|
Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life |
|
Modélisation conjointe de données longitudinales non-linéaires et de données de survie : application au cancer de la prostate métastatique |
|
Modélisation de l'effet de nouvelles molécules anti-VHB chez la souris et chez l'homme |
|
Modélisation de l'effet du favipiravir sur la dynamique viro-immunologique de la maladie à virus Ebola et implications pour son évaluation clinique |
|
Modélisation mathématique de la dégradation des ARNm bactériens et intégration de données omiques |
|
Modélisation mathématique de la différentiation érythrocytaire in vitro. |
|
Modelling the effect of new anti-HBV drugs using animal and clinical data. |
|
Modelling the interaction between danoprevir and mericitabine in the treatment of chronic HCV infection. |
|
Modulation of HCV replication after combination antiretroviral therapy in HCV/HIV co-infected patients. |
|
Multilevel joint modelling of target lesions dynamics and survival : application to the prediction of the response to immunotherapy in bladder cancer. |
|
NIMROD: a program for inference via a normal approximation of the posterior in models with random effects based on ordinary differential equations |
|
Nonlinear Mixed-effect Models for Prostate-specific Antigen Kinetics and Link with Survival in the Context of Metastatic Prostate Cancer: A Comparison by Simulation of Two-stage and Joint Approaches. |
|
Patients with chronic hepatitis C without advanced fibrosis and hepatocellular carcinoma: a retrospective clinical-pathological study |
|
Persistence and clearance of Ebola virus RNA from seminal fluid of Ebola virus disease survivors: a longitudinal analysis and modelling study |
|
Pharmacokinetic and pharmacodynamic modeling of rilpivirine in HIV-1-infected patients treated with the single-tablet regimen rilpivirine/tenofovir disoproxil fumarate/emtricitabine. |
|
Prise en compte de données sous la limite de quantification dans la modélisation de la cinétique virale par des modèles non-linéaires à effets mixtes. |
|
Prise en compte d'événements multiples pour analyser et prédire l'évolution d'un cancer. |
|
Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate |
|
Reply: To PMID 25098971. |
|
Umbilical artery Doppler assessment: a clear disparity in ultrasound practice in a national survey. |
|
Understanding and controlling the spread of multi-resistant bacteria by analyzing and modeling interindividual interactions networks in hospital settings. |
|
Unified approach for extrapolation and bridging of adult information in early-phase dose-finding paediatric studies |
|
Using pharmacokinetic and viral kinetic modeling to estimate the antiviral effectiveness of telaprevir, boceprevir, and pegylated interferon during triple therapy in treatment-experienced hepatitis C virus-infected cirrhotic patients |
|
Using vaccine Immunostimulation/Immunodynamic modelling methods to inform vaccine dose decision-making |
|